News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Geron Corporation (GERN) Says FDA Halts Patient Enrollment In Another Cancer Trial


3/20/2014 7:29:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Geron Corp said the U.S. Food and Drug Administration ordered a halt to new patient enrollments in an early-stage trial of its blood cancer drug, imetelstat, over concerns about liver damage. The halt announced on Thursday was for enrollments in a trial sponsored by Mayo Clinic, and comes a week after the FDA ordered Geron to cease company-sponsored trials of the drug over similar concerns. Imetelstat is Geron's only remaining drug and was touted as the company's savior after curing 22 percent of myelofibrosis patients in a trial last year.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Street Insider
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES